Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

After quiet season for IPOs, Third Harmonic set to test investor appetite

The three-year-old biotech, advancing a c-Kit inhibitor to treat hives, could be the first to raise at least $150M in a NASDAQ IPO since April

By Paul Bonanos, Associate Editor
September 9, 2022 8:38 PM UTC

Third Harmonic has proposed terms for what could be the largest biotech IPO in months, as a sector thirsty for liquidity watches to see if investor demand will meet the company’s expectations.

In a regulatory filing late Thursday, Third Harmonic Bio Inc. proposed to sell 9 million shares at $16-$18. At the range’s $17 midpoint, the company would raise $153 million at a postmoney valuation of $625.5 million. According to a calendar posted on NASDAQ.com, the offering is due to price ahead of the session on Thursday, Sept. 15...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Third Harmonic Bio Inc.